Sarah Anderson, oncology strategy lead director, Novotech, discusses the significance of triple-negative breast cancer ...

Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...

PARP inhibitor treatment can induce various resistance mechanisms, including re-activating BRCA mutations, mutations in HR-inhibiting genes and upregulation of drug efflux pumps. Clinical ...

Cite this: Markers of Bone Metabolism in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer - Medscape - May 01, 2009.

Primary GC cells were derived from ascites of a FGFR2-amplified GC patient who was resistant to FGFR2 inhibitors. Primary human peripheral blood mononuclear cells (PBMCs) were separated from human ...

Through phase III clinical trials, PARP inhibitors have demonstrated outcome improvements in mCRPC patients with alterations in BRCA1/2 genes who have progressed on a second-generation androgen ...

The inclusion criteria were as follows (1): Histologically confirmed epithelial ovarian cancer (2); Patients received surgery combined with platinum-containing chemotherapy as first-line treatment (3) ...